Daewoong Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Daewoong Pharma is listed on KOSPI and classified under Health Care, Pharmaceuticals. Its market value is US$921.7M. In FY2025 it reported revenue of US$1.2B and operating profit of US$148.5M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Daewoong Pharma in five facts
Where is Daewoong Pharma listed and in which sector?
Daewoong Pharma (Korean name: 대웅제약) trades under KRX code 069620 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Daewoong Pharma?
Its market capitalisation was US$921.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Daewoong Pharma's latest annual revenue and operating profit?
For fiscal year 2025, Daewoong Pharma reported revenue of US$1.2B, operating profit of US$148.5M and net income of US$145.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 10.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Results of extraordinary shareholders' meetingSep 9
- Appointment/dismissal/resignation of an independent directorSep 9
- Decision to guarantee a third party's debtSep 4
- DisclosureSep 2
- Operating results (preliminary) (fair disclosure)
Daewoong Pharma filed provisional (unaudited) separate results for Q2 2026: revenue of US$277M (+10% year on year), operating profit of US$53.5M (+23.4% year on year) and net income of US$48.1M (+41.9% year on year).
Earnings · Jul 29 - Supply contract signed
Daewoong Pharma disclosed a supply contract with Acino Pharma AG, worth US$59.9M, about 5.89% of its recent annual revenue, running through Jun 2036.
Supply contract · Jun 26 - Operating results (preliminary) (fair disclosure)
Daewoong Pharma filed provisional (unaudited) separate results for Q1 2026: revenue of US$225M (+6.2% year on year), operating profit of US$18.4M (−34.7% year on year) and net income of US$23.5M (+20.3% year on year).
Earnings · May 12 - Cash/in-kind dividend decision
Daewoong Pharma declared a cash dividend of US$0.42 per share.
Dividend · Feb 25 - Supply contract terminatedSupply contract · Feb 12
- Operating results (preliminary) (fair disclosure)
Daewoong Pharma filed provisional (unaudited) separate results for Q4 2025: revenue of US$243M (+8.7% year on year), operating profit of US$31.1M (+8.97% year on year) and net income of US$30.4M (from a loss a year earlier).
Earnings · Feb 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Daewoong Pharma reported consolidated results for FY2025: revenue of US$1.07B (+10.4% year on year), operating profit of US$135M (+33% year on year) and net income of US$131M (+721.1% year on year).
Earnings · Feb 9